Discovery of MRSA active antibiotics using primary sequence from the human microbiome. Academic Article uri icon

Overview

abstract

  • Here we present a natural product discovery approach, whereby structures are bioinformatically predicted from primary sequence and produced by chemical synthesis (synthetic-bioinformatic natural products, syn-BNPs), circumventing the need for bacterial culture and gene expression. When we applied the approach to nonribosomal peptide synthetase gene clusters from human-associated bacteria, we identified the humimycins. These antibiotics inhibit lipid II flippase and potentiate β-lactam activity against methicillin-resistant Staphylococcus aureus in mice, potentially providing a new treatment regimen.

publication date

  • October 17, 2016

Research

keywords

  • Anti-Bacterial Agents
  • Biological Products
  • Drug Discovery
  • Methicillin-Resistant Staphylococcus aureus
  • Microbiota

Identity

PubMed Central ID

  • PMC5117632

Scopus Document Identifier

  • 84991660862

Digital Object Identifier (DOI)

  • 10.1038/nchembio.2207

PubMed ID

  • 27748750

Additional Document Info

volume

  • 12

issue

  • 12